Kala Bio (KALA) Total Current Liabilities (2016 - 2026)
Kala Bio (KALA) posted Total Current Liabilities of $1.6 million for Q1 2026, down 37.57% sequentially from $2.5 million in Q4 2025, and down 93.22% YoY from $23.0 million in Q1 2025.
Kala Bio (KALA) Total Current Liabilities (2016 - 2026) Analysis & Trends
Kala Bio has reported Total Current Liabilities for 11 years, with the latest figure at $1.6 million in Q1 2026.
- Quarterly Total Current Liabilities fell 93.22% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 93.22% YoY) and the FY2025 annual result came in at $2.5 million, down 85.29% from the prior year.
- Total Current Liabilities eased to $1.6 million in Q1 2026 per KALA's latest filing, from $2.5 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $40.2 million in Q3 2022 and troughed at $1.6 million in Q1 2026.
- A 5-year average of $18.7 million and a median of $17.0 million in 2024 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Current Liabilities jumped 131.7% in 2024, then plunged 93.22% in 2026.
- Over 5 years, Total Current Liabilities stood at $25.7 million in 2022, then slumped by 67.51% to $8.3 million in 2023, then surged by 103.16% to $17.0 million in 2024, then tumbled by 85.29% to $2.5 million in 2025, then sank by 37.57% to $1.6 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $1.6 million, $2.5 million, and $32.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.56 Mn |
| Dec 31, 2025 | 2.49 Mn |
| Sep 30, 2025 | 32.57 Mn |
| Jun 30, 2025 | 16.02 Mn |
| Mar 31, 2025 | 22.98 Mn |
| Dec 31, 2024 | 16.96 Mn |
| Sep 30, 2024 | 23.87 Mn |
| Jun 30, 2024 | 19.19 Mn |
| Mar 31, 2024 | 11.88 Mn |
| Dec 31, 2023 | 8.35 Mn |
| Sep 30, 2023 | 10.30 Mn |
| Jun 30, 2023 | 9.85 Mn |
| Mar 31, 2023 | 10.27 Mn |
| Dec 31, 2022 | 25.69 Mn |
| Sep 30, 2022 | 40.24 Mn |
| Jun 30, 2022 | 32.89 Mn |
| Mar 31, 2022 | 32.76 Mn |
| Dec 31, 2021 | 37.42 Mn |
| Sep 30, 2021 | 27.20 Mn |
| Jun 30, 2021 | 26.08 Mn |